<DOC>
	<DOC>NCT00497991</DOC>
	<brief_summary>The purpose of this study is to assess safety and tolerability of multiple ascending doses of AZD1152 and to assess effect of AZD1152 on the rate of complete remission in patients with relapsed acute myeloid leukaemia.</brief_summary>
	<brief_title>Safety, Tolerability, PK and Efficacy of AZD1152 in Patients With Relapsed Acute Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myeloid, Acute</mesh_term>
	<criteria>Relapsed or refractory AML for which no standard therapies are anticipated to result in durable remission Newly diagnosed AML who are not considered suitable for other treatments. Previous myeloablative therapy allogeneic bone marrow or stem cell transplantation, radiotherapy or chemotherapy within 4 weeks of first dose. Participation in any other trial with an investigational product within the previous 30 days Other active malignancy.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>AML</keyword>
	<keyword>phase I/II</keyword>
	<keyword>AZD1152</keyword>
	<keyword>Acute Myeloid Leukaemia</keyword>
</DOC>